Causalidade em farmacoepidemiologia e farmacovigilância: uma incursão teórica

Abstract

ABSTRACT:The article presents some considerations about causality in Pharmacoepidemiology and Pharmacovigilance. To begin, we provide a brief introduction about the importance of the issue, noting that the understanding of causal relationships is considered one of science's greatest achievements and has been, over time, a continuous and central concern of philosophers and epidemiologists. Next, we describe definitions and types of causes, demonstrating their influences on pharmacoepidemiological thought. After that, we present Rothman's multi-causal model as one of the founding explanations of multiple causality and the issue of causality assessment. We conclude with some comments and reflections on causality from the perspective of health surveillance, particularly with regard to regulations on pharmacovigilance.

Reações adversas a medicamentos em pacientes com COVID-19 no Brasil: análise das notificações espontâneas do sistema de farmacovigilância brasileiro

“…In practice, few reactions are considered "defined" and this is due to the complexity of evaluating a causal relationship between a drug and an adverse reaction. This is because there are multiple approaches and different scenarios that can bring uncertainties regarding the causal link of the reaction, including the underlying disease itself (as a confounding factor), competing with the drug for the cause of the reaction 20 .…”

Causalidade e Fonoaudiologia: abordagem epidemiológica

“…In this model, the causal agent may be composed of a constellation of causes, sufficient of an adverse event. The model further explains that different causal components act in groups to produce an effect, necessarily implying that the component causes must act at the same time (15) .…”

The role of pharmacovigilance in patient safety in the COVID-19 pandemic

“…(34) The limitations related to safety data resulting from clinical trials in the pre-marketing phase are well known. Studies report that around 50% of approved drugs can cause adverse reactions that were not detected before their registration (35).…”